MCK

Mckesson Corp

$812.28 +6.32 (+0.78%) At close · Jul 13

Market Cap

$97.64B

120,204,051

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$403.43B +12.4%

FY2026

Net Income

$4.76B +44.5%

FY2026

Gross Margin

3.61% -0.1pp

FY2026

Operating Margin

1.54% +0.3pp

FY2026

Diluted EPS

$38.38 +49.2%

FY2026

Operating Cash Flow

$6.16B +1.2%

FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2027 (G)	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	+13.4%	+11.1%	+7.8%	—	$403.43B	$359.05B	$308.95B	$276.71B	$263.97B	$238.23B	$231.05B	$214.32B	$208.36B	$198.53B	$190.88B	$179.05B	$137.39B	$122.2B	$122.32B	$112.08B	$108.7B	$106.63B	$101.7B
Cost of Revenue	+13.7%	+11.5%	+8.0%	—	$388.88B	$345.73B	$296.12B	$264.35B	$250.84B	$226.08B	$219.03B	$202.57B	$197.17B	$187.26B	$179.47B	$167.63B	$129.04B	$115.32B	$115.92B	$106.11B	$103.03B	$101.25B	$96.69B
Gross Profit	+5.6%	+3.7%	+2.5%	—	$14.55B	$13.32B	$12.83B	$12.36B	$13.13B	$12.15B	$12.02B	$11.75B	$11.18B	$11.27B	$11.42B	$11.41B	$8.35B	$6.88B	$6.4B	$5.97B	$5.68B	$5.38B	$5.01B
Gross Margin	—	—	—	—	3.61%	3.71%	4.15%	4.47%	4.97%	5.1%	5.2%	5.48%	5.37%	5.68%	5.98%	6.37%	6.08%	5.63%	5.23%	5.33%	5.22%	5.04%	4.93%
Research & Development	-34.5%	-24.5%	-12.8%	—	—	—	—	—	—	—	$96M	$71M	$125M	$341M	$392M	$392M	$457M	$433M	$402M	$407M	$376M	$364M	$347M
Selling & Marketing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$805M	$764M	$767M	—	—	—
General & Administrative	+11.8%	+8.6%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$2.35B	$2.07B	$1.84B	$1.68B	$1.64B	$1.56B
Selling, General & Administrative	+1.4%	-1.8%	+0.9%	—	$8.1B	$8.51B	$8.66B	$7.78B	$10.54B	$8.85B	$9.18B	$8.44B	$8.14B	$7.45B	$7.38B	$7.9B	$5.39B	$4.11B	$3.73B	—	—	—	—
Amortization of Intangibles	+5.4%	-8.1%	-4.4%	—	$276M	$226M	$249M	$236M	$332M	$422M	$462M	$485M	$503M	$444M	$431M	$494M	$319M	$215M	$191M	$132M	—	—	—
Depreciation & Amortization	+1.8%	-3.6%	-10.7%	—	$287M	$272M	$279M	$272M	$312M	$344M	$335M	$317M	$951M	$910M	$885M	$1.02B	$735M	$581M	$493M	$496M	$477M	$313M	—
Restructuring Charges	+5.4%	+2.3%	+0.7%	—	$245M	$344M	$115M	$209M	$245M	$219M	$156M	$352M	$13M	$14M	$229M	—	—	—	—	—	—	—	—
Total Operating Expenses	+1.5%	-13.5%	+0.6%	—	$8.34B	$8.9B	$8.92B	$7.98B	$11.09B	$17.19B	$9.53B	$10.87B	$10.42B	$4.15B	$7.87B	$8.44B	$5.91B	$4.53B	$4.28B	$4.15B	$3.67B	$4.18B	$3.53B
Operating Income	+12.3%	—	+5.8%	—	$6.21B	$4.42B	$3.91B	$4.38B	$2.04B	-$5.04B	$2.49B	$886M	$762M	$7.12B	$3.55B	$2.97B	$2.44B	$2.35B	$2.12B	$1.82B	$2.01B	$1.2B	$1.48B
Operating Margin	—	—	—	—	1.54%	1.23%	1.27%	1.58%	0.77%	-2.12%	1.08%	0.41%	0.37%	3.59%	1.86%	1.66%	1.78%	1.92%	1.74%	1.62%	1.85%	1.12%	1.45%
EBITDA	+11.8%	—	+3.9%	—	$6.5B	$4.69B	$4.19B	$4.65B	$2.35B	-$4.7B	$2.82B	$1.2B	$1.71B	$8.03B	$4.43B	$3.99B	$3.17B	$2.93B	$2.62B	$2.32B	$2.49B	$1.51B	—
Interest Expense	-0.1%	+2.6%	—	—	$247M	$265M	$252M	$248M	$178M	$217M	$249M	$264M	$283M	—	—	—	—	—	—	—	—	—	—
Interest Income	+18.7%	+71.7%	+25.8%	—	$179M	$173M	$118M	$107M	$10M	$12M	$49M	$39M	$48M	$29M	$18M	$20M	$16M	$22M	$19M	$18M	$16M	$31M	—
Other Non-Operating Income	-22.0%	+1.1%	+15.1%	—	$236M	$202M	$132M	$497M	$259M	$223M	$12M	$182M	$130M	$77M	$58M	$63M	$32M	$34M	$20M	$36M	$43M	$12M	$121M
Equity in Earnings of Unconsolidated Entities	+11.9%	-32.0%	-7.3%	—	$7M	$9M	$4M	$5M	$43M	$48M	$36M	$43M	$32M	$30M	$15M	$12M	$0	$3M	$9M	-$6M	$6M	$7M	—
Pretax Income	+10.2%	—	+6.7%	—	$6.2B	$4.36B	$3.79B	$4.63B	$1.93B	-$5.03B	$1.14B	$610M	$239M	$6.89B	$3.25B	$2.66B	$2.17B	$1.95B	$1.89B	$1.64B	$1.86B	$1.06B	—
Income Tax	+6.8%	—	+2.0%	—	$1.1B	$878M	$629M	$905M	$636M	-$695M	$18M	$356M	-$53M	$1.61B	$908M	$815M	$757M	$587M	$514M	$505M	$601M	$241M	$468M
Net Income	+10.2%	—	+7.7%	—	$4.76B	$3.3B	$3B	$3.56B	$1.11B	-$4.54B	$900M	$34M	$67M	$5.07B	$2.26B	$1.48B	$1.26B	$1.34B	$1.4B	$1.2B	$1.26B	$823M	—
Net Margin	—	—	—	—	1.18%	0.92%	0.97%	1.29%	0.42%	-1.91%	0.39%	0.02%	0.03%	2.55%	1.18%	0.82%	0.92%	1.09%	1.15%	1.07%	1.16%	0.77%	—
Net Income Attributable to Noncontrolling Interests	+27.7%	+11.1%	+20.5%	—	$337M	$186M	$158M	$162M	$173M	$199M	$220M	$221M	$230M	$83M	$52M	$67M	-$5M	$0	$0	—	—	—	—
Net Income Available to Common Stockholders	+6.7%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$1.2B	$1.26B	$823M	$990M
Comprehensive Income	+5.7%	—	+7.5%	—	$4.95B	$3.24B	$3.03B	$4.19B	$1.23B	-$4.32B	$1.05B	-$98M	$491M	$4.49B	$2.41B	-$234M	$1.33B	$1.27B	$1.32B	$1.28B	$1.45B	—	—
EPS (Basic) USD/shares	+15.2%	—	+14.7%	—	$38.55	$25.86	$22.54	$25.23	$7.32	-$28.26	$4.98	$0.17	$0.32	$22.95	$9.82	$6.37	$5.51	$5.71	$5.70	$4.65	$4.70	$2.99	$3.40
EPS (Diluted) USD/shares	+15.3%	—	+14.7%	$43.80 – $44.60*	$38.38	$25.72	$22.39	$25.03	$7.23	-$28.26	$4.95	$0.17	$0.32	$22.73	$9.70	$6.27	$5.41	$5.59	$5.59	$4.57	$4.62	$2.95	$3.32
Shares Outstanding (Basic Avg) shares	-4.3%	-5.1%	-6.0%	—	123.6M	127.4M	133.2M	141.1M	152.3M	160.6M	180.6M	196.3M	208M	221M	230M	232M	229M	235M	246M	258M	269M	275M	291M
Shares Outstanding (Diluted Avg) shares	-4.4%	-5.0%	-6.1%	—	124.1M	128.1M	134.1M	142.2M	154.1M	160.6M	181.6M	197.3M	209M	223M	233M	235M	233M	239M	251M	263M	273M	279M	298M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2026: $34.06B in buybacks, $4.55B in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

EV/EBIT

—

P/E (TTM)

21.16×

Medical Distribution median 23.46×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31
North American Pharmaceutical Segment	$336,652,000,000	$304,507,000,000	$261,368,000,000	—	—	—	—	—
Oncology and Multispecialty Segment	$48,423,000,000	$36,862,000,000	$30,490,000,000	—	—	—	—	—
Medical Surgical Solutions Segment	$11,507,000,000	$11,380,000,000	$11,309,000,000	$11,110,000,000	$11,608,000,000	$10,099,000,000	$8,305,000,000	$7,618,000,000
Prescription Technology Solutions Segment	$5,805,000,000	$5,216,000,000	$4,769,000,000	$4,387,000,000	$3,864,000,000	$2,890,000,000	$2,705,000,000	$2,489,000,000
International Segment	—	—	—	$20,598,000,000	$36,345,000,000	$35,965,000,000	$38,341,000,000	$38,023,000,000
US Pharmaceutical Segment	—	—	—	$240,616,000,000	$212,149,000,000	$189,274,000,000	$181,700,000,000	$166,189,000,000

By Geography (USD)

Component	2020-03-31	2019-03-31	2018-03-31
United States	$192,709,000,000	$176,296,000,000	$169,943,000,000
Non Us	$38,342,000,000	$38,023,000,000	$38,414,000,000

Key facts CIK 927653 CUSIP 58155Q103 13F (30d) 239 filings 199 filers Visit website Investor relations